A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells

Pharmaceutical Research

Volumn 23, Issue 7, 2006, Pages 1574-1585

  Wong, Ho Lun ^a   Rauth, Andrew M ^b   Bendayan, Reina ^a   Manias, Janet L ^a   Ramaswamy, Manisha ^a   Liu, Zengshe ^c   Erhan, Sevim Z ^c   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c U S DEPARTMENT OF AGRICULTURE   (United States)

Author keywords

Breast cancer cells; Doxorubicin delivery; In vitro cytotoxicity; Multidrug resistance; Polymer lipid hybrid nanoparticles

Indexed keywords

ANION; CATION; DOXORUBICIN; EXCIPIENT; LIPID; NANOPARTICLE; POLYMER; SOYBEAN OIL; TRYPAN BLUE; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL KILLING; CELL STRAIN MDA435 LCC6 MDR1; CLONOGENIC ASSAY; CONTROLLED STUDY; DISPERSION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; DRUG UPTAKE; ENCAPSULATION; FLUOROMETER; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PARTICLE SIZE; PRIORITY JOURNAL; SOLID; SPECTROPHOTOMETRY;

ALKANES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPOXY COMPOUNDS; HUMANS; NANOSTRUCTURES; P-GLYCOPROTEIN; POLYMERS; SOLUBILITY; SOYBEAN OIL; SURFACE PROPERTIES; TIME FACTORS; TRANSFECTION;

EID: 33745588040     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0282-x     Document Type: Article

References (44)

1. P. E. Lonning 2003 Study of suboptimum treatment response: lessons from breast cancer Lancet Oncol. 4 177 185
2. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomized trials Lancet 352 930 942
3. M. M. Gottesman 2002 Mechanisms of cancer drug resistance Annu. Rev. Med. 53 615 627
4. F. Leonessa R. Clarke 2003 ATP binding cassette transporters and drug resistance in breast cancer Endocr.-Relat. Cancer 10 43 73
5. I. Mohamed R. T. Skeel 2003 Carcinoma of breast R. T.. T. Skeel Handbook of Cancer Chemotherapy Lippincott Williams & Wilkins Philadelphia 269 293
6. H. C. Chung S. Y. Rha J. H. Kim J. K. Roh J. S. Min K. S. Lee B. S. Kim K. B. Lee 1967 P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer Breast Cancer Res. Tr. 42 65 72
7. Z. Liu X. Y. Wu R. Bendayan 1999 In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells J. Pharm. Sci. 88 412 418
8. R. Y. Cheung A. M. Rauth X. Y. Wu 2005 In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations Anti-Cancer Drugs 16 4 423 433
9. R. Cheung Y. Ying A. M. Rauth N. Marcon X. Y. Wu 2005 Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C Biomaterials 26 5375 5385
10. Z. Liu R. Cheung X. Y. Wu J. R. Ballinger R. Bendayan A. M. Rauth 2001 A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres J. Control. Release 77 213 224
11. S. C. J. Steiniger J. Kreuter A. S. Khalansky I. N. Skidan A. I. Bobruskin Z. S. Smirnova S. E. Severin R. Uhl M. Kock K. D. Geiger S. E. Gelperina 2004 Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles Int. J. Cancer 109 759 767
12. S. E. Gelperina A. S. Khalansky I. N. Skidan Z. S. Smirnova A. I. Bobruskin S. E. Severin B. Turowski F. E. Zanella J. Kreuter 2002 Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma Toxicol. Lett. 126 131 141
13. M. I. Koukourakis S. Koukouraki I. Fezoulidis G. Kurias S. Archimandritis N. Karkavitsas 2000 High intratumoral accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic tumours Br. J. Cancer 83 1281 1286
14. U. Massing S. Fuxius 2000 Liposomal formulations of anticancer drugs: selectivity and effectiveness Drug Resist. Updat. 3 171 177
15. Z. Liu J. R. Ballinger A. M. Rauth R. Bendayan X. Y. Wu 2003 Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres J. Pharm. Pharmacol. 55 1063 1073
16. Z. Liu R. Bendayan X. Y. Wu 2001 Triton-X-100-modified polymer and microspheres for reversal of multidrug resistance J. Pharm. Pharmacol. 53 1 12
17. Z. Liu X. Y. Wu R. Bendayan 1999 In vitro investigation of ionic polysaccharide microspheres for simultaneous delivery of chemosensitizer and antineoplastic agent to multidrug-resistant cells J. Pharm. Sci. 88 412 418
18. J. Huwyler A. Cerletti G. Fricker A. N. Eberle J. Drewe 2002 By-passing of P-glycoprotein using immunoliposomes J. Drug Target. 10 73 79
19. C. Mamot D. C. Drummond K. Hong D. B. Kirpotin J. W. Park 2003 Liposome-based approaches to overcome anticancer drug resistance Drug Resist. Updat. 6 271 279
20. C. E. Soma C. Dubernet D. Bentolila S. Benita P. Couvreur 2000 Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles Biomaterials 21 1 7
21. L. Fenart A. Casanova B. Dehouck C. Duhem S. Slupek R. Cecchelli D. Betbeder 1999 Evaluation of effect of charge and lipid coating on ability of 60 nm nanoparticles to cross an in vitro model of the blood-brain barrier J. Pharmacol. Exp. Ther. 291 1017 1022
22. A. C. de Verdiere C. Dubernet F. Nemati E. Soma M. Appel J. Ferte S. Bernard F. Puisieux P. Couvreur 1997 Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action Br. J. Cancer 76 198 205
23. C. E. Soma C. Dubernet G. Barratt F. Nemati M. Appel S. Benita P. Couvreur 1999 Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages Pharm. Res. 16 1710 1716
24. A. R. Thierry D. Vige S. S. Coughlin J. A. Belli A. Dritschilo A. Rahman 1993 Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes FASEB J. 7 572 579
25. Y. Romsicki F. J. Sharom 1999 The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter Biochemistry 38 6887 6896
26. Y. L. Lo 2000 Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats Biochem. Pharmacol. 60 1381 1390
27. R. H. Muller K. Mader S. Gohla 2000 Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art Eur. J. Pharm. Biopharm. 50 161 177
28. R. H. Muller D. Ruhl S. Runge K. Schulze-Forster W. Mehnert 1997 Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant Pharm. Res. 14 458 462
29. J. M. Koziara P. R. Lockman D. D. Allen R. J. Mumper 2004 Paclitaxel nanoparticles for the potential treatment of brain tumors J. Control. Release 99 259 269
30. R. Cavalli O. Caputo M. R. Gasco 1993 Solid lipospheres of doxorubicin and idarubicin Int. J. Pharm. 89 R9 R12
31. L. Serpe M. G. Catalano R. Cavalli E. Ugazio O. Bosco R. Canaparo E. Muntoni R. Frairia M. R. Gasco M. Eandi G. P. Zara 2004 Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line Eur. J. Pharm. Biopharm. 58 673 680
32. A. Miglietta R. Cavalli C. Bocca L. Gabriel M. R. Gasco 2000 Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel Int. J. Pharm. 210 61 67
33. S. M. Hahn A. Russo J. A. Cook J. B. Mitchell 1999 A multidrug-resistant breast cancer line induced by weekly exposure to doxorubicin Int. J. Oncol. 14 273 279
34. H. L. Wong R. Bendayan A. M. Rauth X. Y. Wu 2004 Development of solid lipid nanoparticles containing ionically-complexed chemotherapeutic drugs and chemosensitizers J. Pharm. Sci. 93 1993 2004
35. MDR1: ascites models of human breast cancer Br. J. Cancer 73 154 161
36. R.G. Bristow R.P. Hill 1998 Molecular and cellular basis of radiotherapy I. F. Tannock R. P. Hill The Basic Science of Oncology McGraw-Hill Toronto 295 321
37. Z. Liu and S. Erhan. Synthesis and properties of new soybean oil based polymers, US patent application.
38. D. Z. Hou C. S. Xie K. J. Huang C. H. Zhu 2003 The production and characteristics of solid lipid nanoparticles (SLNs) Biomaterials 24 1781 1785
39. J. Moselhy X. Y. Wu R. Nicholov K. Kodaria 2000 In vitro characterization of interaction of poly(NIPAm/MAA) nanoparticles with proteins and cells J. Biomater. Sci. Polym. Ed. 11 123 147
40. S. L. Abrahamse B. L. Pool-Zobel G. Rechkemmer 1999 Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells Carcinogenesis 20 629 634
41. A. V. Kabanov E. V. Batrakova V. Y. Alakhov 2002 Pluronic block copolymers for overcoming drug resistance in cancer Adv. Drug Deliv. Rev. 54 759 779
42. E. V. Batrakova S. Lee S. Li A. Venn V. Alakhov A. Kabanov 1999 Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells Pharm. Res. 16 1373 1379
43. J. Kreuter P. Ramge V. Petrov S. Hamm S. E. Gelperina B. Engelhardt R. Alyautdin H. von Briesen D. J. Begley 2003 Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 409 416
44. A. Tang P. Kopeckova J. Kopecek 2003 Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes Pharm. Res. 20 360 367